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ABSTRACT
Adenoid cystic carcinoma (AdCC) is among the
most common malignant tumors of the salivary
glands. It is characterized by a prolonged
clinical course, with frequent local recurrences,
late onset of metastases and fatal outcome.
High-grade transformation (HGT) is an
uncommon phenomenon among salivary
carcinomas and is associated with increased
tumor aggressiveness. In AdCC with high-grade
transformation (AdCC–HGT), the clinical
course deviates from the natural history of
AdCC. It tends to be accelerated, with a high
propensity for lymph node metastasis. In order
to shed light on this rare event and, in
particular, on treatment implications, we
undertook this review: searching for all
published cases of AdCC-HGT. We conclude
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that it is mandatory to perform elective neck
dissection in patients with AdCC-HGT, due to
the high risk of lymph node metastases
associated with transformation.
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REVIEW
The concept of high-grade transformation
(previously also termed dedifferentiation) in
neoplasms was introduced in 1971. Dahlin and
Beabout [1] described a distinct entity in which a
low grade chondrosarcoma was associated with a
histologically high-grade sarcoma. High-grade
transformation (HGT) in salivary gland tumors
is rare but has been described not only in
adenoid cystic carcinoma (AdCC) but in acinic
cell carcinoma (AcCC) [2–7], polymorphous
low-grade adenocarcinoma [8–10],
epithelial-myoepithelial carcinoma [11–14],
low-grade mucoepidermoid carcinoma [15],
myoepithelial carcinoma [16], hyalinizing clear
cell carcinoma [17, 18], and mammary analogue
secretory carcinoma (MASC) [19, 20]. The
molecular genetic mechanisms responsible for
these transformations remain largely unknown
but a few genes have been documented in HGT
of salivary gland neoplasms, such as P53 gene
mutation and C-MYC amplification [21–24].
HGT in salivary tumors of low-grade
malignancy, such as AcCC, is associated with a
higher local recurrence rate, a higher propensity
for local lymph node metastasis and, a dramatic
worsening of prognosis. For example, AcCC has
the best prognosis of all salivary malignancies
(10-year survival *90%), but HGT in AcCC
significantly reduces the mean survival of
patients to 4.3 years [5, 25].
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HGT in AdCC (AdCC-HGT) was first
described in 1999 by Cheuk et al. [26] as
‘‘dedifferentiated adenoid cystic carcinoma’’
and since then more than 40 cases have been
reported in the literature, most of them
involving sinonasal and palatal minor glands
and the submandibular glands [21, 23, 26–42].
AdCC-HGT is histologically characterized by a
residual component of conventional AdCC and
another distinct anaplastic cell population
showing loss of the biphasic ductal and
myoepithelial differentiation seen in
conventional AdCC. HGT in AdCC may be
apparent at the time of primary excision of the
tumor or may develop in a recurrence [26]. The
two components may be separate, but
transitional zones can be recognized. The
presence of a transitional zone may help to
distinguish AdCC-HGT from a hybrid tumor in
which one of the two components is an AdCC.
It may also be that many of the hybrid tumors
[43] reported in the literature represent HGT in
different salivary tumors. The distinction
between the solid type of AdCC and
AdCC-HGT should be emphasized. The
histological criteria distinguishing between the
two have been outlined in 2007 by Seethala
et al. [33]. The solid type of AdCC is known to
have the worst prognosis of the different
histological subtypes of conventional AdCCs.
Distant metastasis developed in 73% of major
salivary gland solid type AdCC compared to 8%
and 17% in cribriform and tubular types,
respectively [44]. Most reports indicate that
the prognosis for patients with AdCC-HGT is
even worse than for those with a solid type of
AdCC [24, 33, 36] and thus its recognition is
important for the individual patient. The cells
in the solid type of AdCC have small
hyperchromatic nuclei and a basaloid
appearance; the transformed cells in
AdCC-HGT have larger and more
pleomorphic, vesicular nuclei. The
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tubular-cribriform component of AdCC retains
some of the myoepithelial immunoprofile. The
conventional AdCC component in AdCC-HGT
can have any mixture of growth patterns, with
predominance of the cribriform and tubular
patterns. The HGT component, which usually is
either a poorly differentiated adenocarcinoma,
or less often, an undifferentiated carcinoma,
shows cells with large pleomorphic nuclei and a
high mitotic rate (Fig. 1). The nuclei contain
vesicular chromatin with conspicuous nucleoli.
Necrosis (including comedonecrosis) is
common as is a desmoplastic stroma and,
tumoral calcification. Squamous areas and
micropapillary growth are unique patterns
seen exclusively in AdCC-HGT as compared to
conventional AdCC [33]. There is an altered
immunoprofile detected as a loss of the
abluminal layer of myoepithelial cells [e.g. p63
and other myoepithelial/basal cell markers such
as calponin, smooth muscle actin (SMA) and
smooth muscle myosin heavy chain (SMMHC)],
although there may be S-100 protein
expression. Ki-67 (often more than 50%) and
p53 labeling indices are often elevated while
CD117 is generally lost. In some cases, cyclin
D1 overexpression, as well as p53 abnormalities
in association with Her-2/neu overexpression or
loss of pRb expression, have all been detected in
the AdCC-HGT component [21, 26, 30]. Studies
by Seethala et al. [24] have shown C-MYC
amplification in the process of HGT in AdCCs
while other oncogenes, more frequently on
chromosome 17q23, are also present,
warranting further investigation. Recently,
Costa et al. [45] studied 8 cases of AdCC-HGT
and demonstrated that MYB/NFIB translocation
is not necessarily an early event in or
fundamental for the progression into
AdCC-HGT.
There are statements that AdCC-HGT has a
high propensity for lymph node metastasis,
with as many as 57% of the patients showing
metastatic disease compared to 5–25% of
patients with conventional AdCC (cribriform,
tubular and solid patterns) [33, 46]. The risk for
nodal disease in AdCC-HGT is likely to be
Fig. 1 High-grade transformation in adenoid cystic carci-
noma (AdCC-HGT). a The transformed AdCC consists
of sheets of atypical, cells and loss of architecture usually
seen in a conventional AdCC. b AdCC-HGT with a very
high labeling index with Ki-67 (left) and a much more
modest Ki-67 index in the remnants of the conventional
AdCC (right)
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distinctly higher when compared to
conventional AdCC as many lymph nodes in
cases of conventional AdCC are involved by
direct extension from the primary tumor rather
by a true metastasis as identified in our review
of 44 cases of AdCC-HGT reported in the
literature (Table 1) [21, 23, 26–42, 45, 47].
Kusafuka et al. [48] described a case of early
transformation only and therefore was not
included. Taking into account the possibility
that some or even many of the reported hybrid
tumors may represent HGT in different tumors,
the number of AdCC-HGT could be even
higher. Of the approximately 35 cases of
hybrid tumors reviewed by Hellquist and
Skalova [49], AdCC was the most common
malignancy and was seen in 18 of the 33
malignant cases: two hybrid tumors comprised
benign components only, and all but one of the
remainder had two malignant components. The
present review revealed cervical lymph node
metastasis in 12 of 29 cases of AdCC-HGT. In 17
additional cases, the authors clearly stated there
was no metastasis, while the remaining 15
reports did not include information about
lymph node status. Thus, for the 29 cases in
which information about lymph node
metastasis (present or absent) was given,
positive nodes were reported in 41% (12/29).
In six cases with cervical lymph node metastasis
distant metastases were also reported (50%).
However synchronous or metachronous
presentation could not be assessed in this
review (Table 1). Seethala et al. [33] described
11 cases of AdCC-HGT where 4 of the 11 cases
(36%) had cervical lymph node metastases with
multiple positive nodes and extracapsular
extension in all four cases (5 positive nodes of
29, 2/2, 3/18 and 2/22), a percentage similar to
the literature review.
In the study from the MD Anderson Cancer
Center of 60 patients with early-stage (pT1, pT2)
AdCC of conventional type, seven of the 30
patients who received neck dissection had
occult metastasis (23%). This study primarily
aimed to evaluate the risk for distant metastasis
and survival rather than development of criteria
for neck node dissection, but nevertheless, 43%
of patients who had positive cervical lymph
nodes after neck dissection developed distant
metastasis compared to 17% who did not have
positive nodes or a neck dissection. This study
also demonstrated that 73% of patients with the
solid subtype of conventional AdCC developed
distant metastasis compared to 8% and 17% for
cribriform and tubular subtypes, respectively.
The subtype of AdCC among the seven patients
who developed nodal disease was not
specifically stated [44].
The concept of HGT in AdCC was widely
accepted after the publication of Cheuk et al.
[26] in 1999. There is, however, an uncertain
number of reports of AdCC prior to that date,
which today, according to the histological
description, very likely would have been
classified as AdCC-HGT. As an example, the
1985 report by Stillwagon et al. [50] would fit as
AdCC-HGT: ‘‘Histologically, the tumor was an
adenoid cystic carcinoma with cribriform and
solid areas as well as some areas of
undifferentiated carcinoma’’. For obvious
reasons, it is impossible to review all single
case reports of AdCC in the literature to
document possible cases of AdCC-HGT and,
therefore, only cases classified as AdCC-HGT or
dedifferentiated AdCC, published after 1999
have been included in this review and are
summarized in Table 1. The current review of
AdCC-HGT emphatically demonstrates the
importance of a very generous sampling of the
surgical specimens as the HGT component may
be very small. In fact, ideally the entire tumor
should be sectioned and examined whenever
possible. Not only will careful dissection and
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Table 1 Review of reported cases of adenoid cystic carcinoma with high-grade transformation
Authors
(year)
[references]
No.
of
cases
Age Location Cervical lymph
node
metastasis
Distant metastasis Remarks (gender,
tumor size, status,
follow-up)
Cheuk et al.
(1999) [26]
3 55 Tongue Present Bone, lung F, NA, DOD,
15 months
53 Soft palate Absent Lung F, NA, DOD, 9 months
38 Hard palate Present Absent M, NA, DOD,
18 months
Moles et al.
(1999) [27]
1 61 Tongue NA NA M, 3 cm, NED,
60 months
Terasaki et al.
(2000) [28]
1 49 Lacrimal gland NA NA F, NA, NA, NA
Chau et al.
(2001) [21]
1 64 L submandibular
gland
Present NA F, 3 cm, NED,
6 months
Ide et al.
(2003) [29]
1 62 Soft palate NA NA M, 2.2 cm, NA, NA
Nagao et al.
(2003) [30]
6 55 L maxillary sinus Present Bone, lung F, 6.0 cm, DOD,
6 months
51 R submandibular
gland
Absent Bone M, 4.5 cm, DOD,
24 months
35 L nasal cavity Absent Absent F, 1.8 cm, DOD,
36 months
70 R submandibular
gland
Present Absent M, 3.5 cm, DOD,
69 months
34 R maxillary sinus Present Absent F, NA, AWD,
60 months
36 L nasal cavity Absent Bone, lung M, 1.7 cm, DOD, NA
Brackrock
et al. (2005)
[31]
1 NA NA NA NA HGT ﬁrst after
radiotherapy
Sato et al.
(2006) [32]
1 74 R maxillary sinus Absent Lung, liver, spleen, bone,
pulmonaryhilar lymph
nodes
M, 4 cm, DOD,
4 months
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Table 1 continued
Authors
(year)
[references]
No.
of
cases
Age Location Cervical lymph
node
metastasis
Distant metastasis Remarks (gender,
tumor size, status,
follow-up)
Seethala et al.
(2007) [33]
11 72 R maxillary sinus NA NA M, NA, NA, NA
59 Pterygopalatine Absent Absent M, NA, DOD,
12 months
57 R submandibular Present Lung M, 7 cm, DOD,
15 months
53 L nasal Absent Lung F, 4 cm, DOD,
12 months
62 R submandibular Present NA F, 1.7 cm, Alive,
48 months
61 R paranasal sinus NA NA F, NA, Dead,
44 months
66 R pyriform Absent NA M, 7 cm, Dead,
8 months
32 Maxillary Present NA M, 6 cm, NA, NA
64 R palate Absent NA F, 2.7 cm, AWD,
1 month
42 R submandibular Present Soft tissue M, 3 cm, AWD,
3 months
66 R submandibular Absent Absent M, 2 cm, Alive,
2 months
Handra-Luca
et al. (2009)
[34]
1 51 Maxillary sinus NA Lung F, NA, NA, NA
Malhotra et al.
(2009) [35]
1 54 R parotid NA Absent M, 5 cm, NED,
5 months
Bonﬁtto et al.
(2010) [23]
7 44 Submandibular Absent Absent F, T2, NA, 18 months
55 Palate Absent Absent F, T4, NED,
140 months
65 Paranasal sinus Absent Absent M, T4, Dead, 8 months
49 Parotid Absent Liver F, T3, Alive, 33 months
64 Submandibular Present Liver F, T2, DOD, 7 months
58 Lips Absent Absent F, T2, NED, 18 months
47 Palate Presenta Lung M, T4, Alive,
12 months
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Table 1 continued
Authors
(year)
[references]
No.
of
cases
Age Location Cervical lymph
node
metastasis
Distant metastasis Remarks (gender,
tumor size, status,
follow-up)
Costa et al.
(2011)b [36]
1 61 Paranasal sinus NA Absent F, T2, Alive,
144 months
Panarelli et al.
(2011) [37]
1 52 Lacrimal gland NA NA M, 3.2 cm, AWD,
12 months
Boland et al.
(2012) [38]
3 61 Parotid NA NA F, NA, Alive,
169 months
56 Parotid NA NA M, NA, ANED,
77 months
40 Submandibular NA NA M, NA, ANED,
6 months
Argyris et al.
(2013) [39]
1 39 Lacrimal gland NA NA F, 3 cm, AWD,
24 months
Bayle et al.
(2013) [40]
1 45 Palate NA NA F, 4.5 cm, NA, NA
Ly et al.
(2013) [41]
1 88 Parotid Absent Absent F, 3 cm, Alive,
12 months
Sayar et al.
(2013) [42]
1 39 L submandibular
gland
Absent NA F, 4.0 cm, NED,
36 months
Total Data
Available
44 54.4 2 Tongue
7 Palate
3 Lacrimal gland
11
Submandibular
9 Paranasal sinus
3 Nasal cavity
5 Parotid
3 Other
1 NA
17 Absent
12 Present
15 NA
13 Absent
13 Present
18 NA
Alive alive (no further information), ANED alive with no evidence of disease, AWD alive with disease, Dead dead (no
further information), DOD dead of disease, F female, HGT high-grade transformation, L left, M male, NA information not
available, NED no evidence of disease, No number, R right
a A later study by Costa et al. in 2012 [47] and another one in 2014 [45] comprised 8 cases; 7 of the cases derived from the
2010 study by Bonﬁtto et al. [23] and the additional 8th case from the 2011 study by Costa et al. [36]. In the 2014 study by
Costa et al. [45], it is stated that this same particular palatal tumor did not have any cervical lymph node metastasis
b In the 2011 study, Costa et al. [36] reported 6 cases of AdCC-HGT, however, 5 of the cases were included in the previous
2010 study by Bonﬁtto et al. [23]; hence only one new case presented in this 2011 study by Costa et al. [36]
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histologic evaluation help to identify any
possible focus of HGT, but may also highlight
areas of solid subtype in a conventional AdCC.
CONCLUSION
Based on the literature review, lymph node
metastasis may occur in 43–57% of patients
with AdCC-HGT. This high propensity for
lymph node metastases, which is at least 5–10
times higher than for conventional AdCC,
strongly supports the use of neck dissection
for patients with this unique histology.
Preoperative staging workup is mandatory due
to the high risk of distant metastasis.
In situations where such histology is not
recognized until after extirpative surgery for
the primary, it appears justified to subsequently
include the neck electively in the post-operative
radiotherapy or perform a postoperative elective
neck dissection (if distant metastasis are ruled
out) followed by adjuvant radiation therapy to
the primary site and the regional lymph nodes.
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